Cirrhosis/Liver Failure News

Though absolute differences did not emerge in the treatment of hepatic encephalopathy with L-carnitine, a presenter at the Digital International Liver Congress suggested the changes seen indicate more research with higher doses may be warranted.

In this exclusive video, Jasmohan S. Bajaj, MD, of Virginia Commonwealth University, discusses his study from the Digital International Liver Congress on fecal microbiota transplantation in the setting of alcohol use disorder.

Factors such as national health expenditure and gross domestic product were associated with increase liver-related mortality, according to research published in Clinical Gastroenterology and Hepatology.

Approximately one in six patients with cirrhosis had depression while more than half had moderate-severe anxiety, according to the results of a phone interview survey.

Use of proton pump inhibitors had a dose-dependent association with bone fractures in men with cirrhosis, according to study results.

Increasing per capita coffee consumption on a population level has the potential to avert liver disease-related deaths, according to study results.

A novel drug comprising eight different amino acids showed efficacy in improvement of neurocognitive function, metabolism and other positive outcomes in patients with mild and moderate hepatic insufficiency, according to a press release issued by the manufacturer, Axcella.

Fecal microbiota transplantation was associated with short-term reductions in alcohol craving and consumption in men with alcohol use disorder, according to research published in Hepatology.

Standard of care lifestyle counseling correlated with improvements in nonalcoholic steatohepatitis or fibrosis in half of the children with nonalcoholic fatty liver, according to study results publish in Gastroenterology.

FDA Cardiovascular and Renal Drugs Advisory Committee voted 8-7 to recommend approval of terlipressin for the treatment of hepatorenal syndrome type 1 in patients with cirrhosis.